Wilson PW,Garrison RJ,Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study:role of lipoprotein cholesterols.AmJCardiol 1980;46:649-54.
Stamler J,Wentworth D, Neaton JD.Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?: findings in 356,222 primary screenees of the Multiple Risk FactorInterventionTrial(MRFIT).JAMA1986;256:2823-8.
Anderson KM,Castelli WP, Levy D.Cholesterol and mortality. 30 years of follow-up fromthe Framinghamstudy.JAMA1987;257:2176-80.
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. Therelationship of reduction in incidence ofcoronary heart diseaseto cholesterol lowering.JAMA1984;251:365-74.
Ministry of Health & Welfare.Korea health statistics 2012: Korea National Health and Nutrition Examination Survey (KNHANESV-3) [Internet]. Sejong:Ministry of Health & Welfare; 2012 [cited 2013 Dec 27].
Available form:
http://stat.mw.go.kr/front/statData/publicationView.jsp?menuId=47&bbsSeq=13&nttSeq=21193&searchKey=&searchWord=&nPage=1
Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,andTreatment of High BloodCholesterol inAdults(AdultTreatment PanelIII).JAMA2001;285:2486-97.
GialamasA,Yelland LN,Ryan P,Willson K, Laurence CO,Bubner TK,et al. Does point-of-caretesting lead to thesame or better adherenceto medication?:a randomised controlled trial: the PoCT in General Practice Trial. Med JAust 2009;191:487-91.
Luley C, Ronquist G, Reuter W, Paal V, Gottschling HD,Westphal S,et al. Point-of-care testing of triglycerides:evaluation of theAccutrend triglyceridessystem.ClinChem2000;46:287-91.
GottschlingHD,ReuterW,RonquistG,SteinmetzA,HattemerA.Multicentre evaluation of a non-wipe system for the rapid determination of total cholesterol in capillary blood,AccutrendCholesterol onAccutrendGC.Eur JClinChemClin Biochem1995;33:373-81.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma,without use of the preparative ultracentrifuge.ClinChem1972;18:499-502.
Bachorik PS, Ross JW. National Cholesterol Education Program recommendationsformeasurement of low-density lipoprotein cholesterol:executive summary. The National Cholesterol Education Program Working Group on LipoproteinMeasurement.ClinChem1995;41:1414-20.
Moses RG,Calvert D, Storlien LH. Evaluation of the Accutrend GCT with respectto triglyceridemonitoring.DiabetesCare 1996;19:1305-6.
Greenland P, Bowley NL, Meiklejohn B, Doane KL, Sparks CE. Blood cholesterol concentration: fingerstick plasma vs venous serum sampling. Clin Chem1990;36:628-30.
GialamasA,Laurence CO,Yelland LN,Tideman P,Worley P, Shephard MD, et al.Assessing agreement between point of care and laboratory results for lipid testing froma clinical perspective.Clin Biochem2010;43:515-8.
Scafoglieri A, Tresignie J, Provyn S, Clarys JP, Bautmans I. Reproducibility, accuracy and concordance ofAccutrend Plusfor measuring circulating lipid concentration in adults.BiochemMed (Zagreb) 2012;22:100-8.
Young DS,Bermes EW.Specimen collection and processing:sources of biological variation.In: Burtis CA,Ashwood ER, Tietz NW,editors. Tietz textbook ofclinicalchemistry.Philadelphia (PA):W.B.Saunders; 1999.p.42-72.
McNamara JR,Cohn JS,Wilson PW, Schaefer EJ.Calculated valuesforlowdensity lipoprotein cholesterol in the assessment of lipid abnormalities and coronary diseaserisk.ClinChem1990;36:36-42.
Jun KR, Park HI,Chun S, Park H, MinWK. Effects of totalcholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula.ClinChemLabMed 2008;46:371-5.
Garg A,Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-69.
Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterolratherthan low-density lipoprotein cholesterol as a tool forlipoprotein cholesterol screening and assessment of risk and therapy.Am J Cardiol 1998;81:26B-31B.
Stein JH,Carlsson CM,Papcke-Benson K,Einerson JA,McBride PE,Wiebe DA.Inaccuracy of lipid measurements with the portable Cholestech L.D.X analyzerin patientswith hypercholesterolemia.ClinChem2002;48:284-90.
Dale RA,Jensen LH,Krantz MJ.Comparison of two point-of-carelipid analyzersfor usein globalcardiovascularrisk assessments.Ann Pharmacother 2008;42:633-9.
SanteeJ.Accuracy and precision of theCholestech LDXSysteminmonitoring blood lipid levels.AmJHealth Syst Pharm2002;59:1774-9.